- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02192515
A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects
A Phase 1 Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects
The purpose of this study is to assess the safety and pharmacokinetics of APD356 in healthy Japanese adult subjects. Regarding cohorts 1 to 3, this study is a single center, placebo-controlled, randomized,double-blind study. Regarding cohort 4, this study is a single center, randomized, open-label study that consists of two sequential two-way crossover studies. The study consists of 4 cohorts. In cohort 1, subjects will be randomized to 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug. In cohort 2, subjects will be randomized to 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug. In cohort 3, subjects will be randomized to XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast. In cohort 4, subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.
Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed)
Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted)
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tokyo
-
Toshima-Ku, Tokyo, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Subjects must meet all of the following criteria to be included in this study:
- Non-smoking, healthy Japanese male subjects age greater than or equal to 20 years and less than 55 years old at the time of informed consent. To be considered non-smokers, subject must have discontinued smoking for at least 4 weeks prior to dosing.
BMI greater than or equal to 23 and less than 32 kg/m2 at Screening
a) BMI (kg/m2) = body weight(kg)/[height(m) x height(m)]
- Provide written informed consent
- Willing and able to comply with all aspects of the protocol
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from this study:
- Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
- Evidence of disease that may influence the outcome of the study within 4 weeks prior to dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or subjects who have a congenital abnormality in metabolism
- Any history of gastrointestinal surgery that may affect PK profiles of study drug, eg, hepatectomy, nephrotomy, digestive organ resection at Screening
- Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, ECG finding, or laboratory test results that require medical treatment at Screening
- A prolonged QT/QTc interval (QTc greater than 450 ms) demonstrated on ECG at Screening or Baseline
- Known history of clinically significant drug allergy at Screening
- Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening
- Known to be human immunodeficiency virus (HIV) positive at Screening
- Positive results for Hepatitis B surface antigen (HBs Ag), Hepatitis C virus antibody (HCV Ab) or Syphilis test at Screening
- History of drug or alcohol dependency or abuse, or those who have a positive urine drug test at Screening or Baseline
- Intake of caffeinated beverages or food within 72 hours prior to dosing
- Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (eg, alcohol and grapefruit juice) within 1 week prior to dosing
- Intake of herbal preparations containing St. John's Wort within 4 weeks prior to dosing
- Use of prescription drugs (except for disinfectants, eye drops) within 4 weeks prior to dosing
- Intake of over-the-counter (OTC) medications (except for disinfectants, eye drops) within 2 weeks prior to dosing
- Currently enrolled in another clinical study or used any investigational drug or device within 16 weeks preceding informed consent
- Subjects who undergo blood transfusion within 12 weeks, or who donate 400 mL or more of whole blood within 12 weeks (16 weeks for woman) or 200 mL or more of whole blood within 4 weeks, or who make a component donation within 2 weeks prior to dosing.
- Engagement in strenuous exercise within 2 weeks prior to check-in (eg, marathon runners, weight lifters, etc.)
- Subjects who have any condition that would make them, in the opinion of the investigator, unsuitable for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: APD356 10 mg
Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
|
One tablet of APD356 10 mg will be orally administered in fasted state.
One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
|
Experimental: APD356 20 mg
Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
|
Two tablets of APD356 10 mg will be orally administered in fasted state.
Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
|
Experimental: APD356 XR-20 mg
Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
|
One tablet of APD356 XR-20 mg will be orally administered in fasted state.
One tablet of APD356 XR matching placebo will be orally administered in fasted state.
|
Experimental: APD356 10 mg and APD356 XR-20mg (orange tablet)
Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below. Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed) Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted) |
One tablet of APD356 10 mg will be orally administered in fasted state.
One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety as assessed by adverse events (AEs), clinical laboratory tests, vital signs, body weight and ECGs
Time Frame: Up to 30 days after last dose
|
Up to 30 days after last dose
|
Pharmacokinetics of APD356: Cmax
Time Frame: Up to 96 hours after last dose
|
Up to 96 hours after last dose
|
Pharmacokinetics of APD356: tmax
Time Frame: Up to 96 hours after last dose
|
Up to 96 hours after last dose
|
Pharmacokinetics of APD356: AUC
Time Frame: Up to 96 hours after last dose
|
Up to 96 hours after last dose
|
Pharmacokinetics of APD356: t1/2
Time Frame: Up to 96 hours after last dose
|
Up to 96 hours after last dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- APD356-J081-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on APD356 10 mg
-
Eisai Inc.CompletedObesityUnited States
-
Eisai Inc.CompletedObesityUnited States
-
Eisai Inc.Completed
-
Eisai Inc.Completed
-
Eisai Inc.Completed
-
Eisai Inc.Completed
-
Merck Sharp & Dohme LLCCompleted
-
PfizerCompleted
-
Eisai Inc.Completed
-
Idorsia Pharmaceuticals Ltd.Completed